Neuren Pharmaceuticals (ASX:NEU) said its partner, Nasdaq-listed Acadia Pharmaceuticals, agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million, according to a Wednesday filing with the Australian bourse.
The company is entitled to one-third of the proceeds of the sale under its license agreement with Acadia, according to the filing.
The PRV was granted by the US Food and Drug Administration after the approval of Daybue for Rett syndrome treatment, the filing said.
Neuren Pharmaceuticals shares rose past 6% in midday trade Wednesday.
Price (AUD): $13.04, Change: $+0.77, Percent Change: +6.28%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.